4/A//SEC Filing
Huyett William 4/A
Accession 0001209191-19-050308
CIK 0001755237other
Filed
Sep 19, 8:00 PM ET
Accepted
Sep 20, 4:01 PM ET
Size
13.0 KB
Accession
0001209191-19-050308
Insider Transaction Report
Form 4/AAmended
Huyett William
DirectorPRESIDENT
Transactions
- Award
Employee Stock Option (Right to Buy)
2019-04-01+221,964→ 221,964 totalExercise: $14.21Exp: 2029-01-29→ Common Stock (221,964 underlying) - Award
Common Stock
2019-04-01+39,172→ 78,898 total - Award
Common Stock
2019-04-01+38,320→ 38,320 total - Award
Employee Stock Option (Right to Buy)
2019-04-01+221,312→ 221,312 totalExercise: $16.82Exp: 2028-01-02→ Common Stock (221,312 underlying)
Footnotes (7)
- [F1]In connection with the separation of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals Inc. ("Ironwood") effective April 1, 2019 (the "Separation"), the reporting person received a grant of 38,320 restricted stock units, each representing the right to receive a share of Cyclerion common stock, as a result of the adjustment of existing Ironwood restricted stock units held by the reporting person prior to the Separation. The restricted stock unit award, granted as an annual performance award, vests as to 25% of the shares of common stock on the approximate anniversary of the grant.
- [F2]This report has been amended to reflect the number of options that were assumed by the Issuer under its applicable mirror equity plan as a result of the Separation.
- [F3]In connection with the Separation, the reporting person received a grant of 39,172 restricted stock units, each representing the right to receive a share of Cyclerion common stock, as a result of the adjustment of existing Ironwood restricted stock units held by the reporting person prior to the Separation. The restricted stock unit award, granted as an annual performance award, vests as to 25% of the shares of common stock on the approximate anniversary of the grant.
- [F4]This report has been amended to reflect the number of shares received in a pro rata distribution as a result of the Separation.
- [F5]This report has been amended to correct the exercise price of the stock options that were originally issued by Ironwood in connection with the Separation.
- [F6]The option, granted as a new hire award, vested as to 25% of the shares of common stock on December 15, 2018, and 2.08333% of the shares of common stock vest each month thereafter for the next 36 months.
- [F7]The option, granted as an annual performance award, vests as to 2.08333% of the shares of common stock on each monthly anniversary of January 1, 2019.
Documents
Issuer
Cyclerion Therapeutics, Inc.
CIK 0001755237
Entity typeother
Related Parties
1- filerCIK 0001723846
Filing Metadata
- Form type
- 4/A
- Filed
- Sep 19, 8:00 PM ET
- Accepted
- Sep 20, 4:01 PM ET
- Size
- 13.0 KB